Form 4: Exact Sciences Executive Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Exact Sciences SVP James Herriott sold 1,500 shares of common stock for $70.08 per share under a pre-arranged 10b5-1 trading plan.
Summary
- James Herriott, SVP, General Counsel & Secretary of Exact Sciences Corp. (EXAS), reported a sale of common stock.
- On November 4, 2025, Herriott sold 1,500 shares of EXAS common stock at a price of $70.08 per share.
- This transaction was executed pursuant to a Rule 10b5-1 trading plan established on March 3, 2025.
- Following the sale, Herriott directly owns 12,585 shares of common stock and indirectly owns 1,556 shares held in a 401(k) Plan, totaling 14,141 shares.
- Additionally, Herriott holds 37,434 vested and unvested options to purchase shares of common stock and restricted stock units.
Sentiment
Score: 5
Explanation: The filing reports a pre-scheduled insider stock sale, which is a routine disclosure and does not inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Industry Context
This is a routine insider transaction report and does not provide specific industry context or trends. Insider sales under a 10b5-1 plan are common for executives managing personal finances and diversifying holdings.
Stakeholder Impact
- Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal impact on shareholder sentiment, as it is a pre-planned event rather than a reaction to new company developments.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date Rule 10b5-1 trading plan was entered into. |
| 11/04/2025 | Date of the reported transaction (sale of common stock). |
| 11/06/2025 | Date the Form 4 was signed by attorney-in-fact. |
Keywords
Exact Sciences, EXAS, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, James Herriott
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.